Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN
About this episode
This episode discusses the evolving roles of MEK inhibitors in the treatment of plexiform neurofibromas associated with neurofibromatosis type 1.
Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform neurofibromas (PNs), which can cause significant morbidity due to pain, disfigurement, neurologic impairment, and risk of malignant transformation. Despite advances in understanding NF1 biology, care remains complex and often fragmented across specialties, leading to delayed rec...
More episodes of CEConversations
- A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC
- Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies
- Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors
- MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management
- Desmoid Tumors in Focus: Early Recognition, Evolving Therapies, and Nursing-Led Care Strategies
- The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations
Explore listener stats, chart rankings, contacts and more on the CEConversations podcast page.